Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycopyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycopyrronium SCHEMBL41436 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL1900235 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL417981 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL417980 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL132614 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL2335685 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL131054 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL4106576 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5391795 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL915388 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | claimed |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | claimed |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2013-09-12 | — | — | US | claimed |
| CN-102858640-B | Be provided for the method for the filling tank of inhaler | ASTRAZENECA UK LTD. (GB) | 2015-12-09 | — | — | CN | disclosed |
| CN-103118727-B | Inhaler | ASTRAZENECA AB (SE) | 2015-11-25 | — | — | CN | disclosed |
| CN-103118726-B | Inhaler | ASTRAZENECA AB | 2015-07-22 | — | — | CN | disclosed |
| CN-102176939-B | Inhaler with audible indicator means | ASTRAZENECA SWEDEN AB | 2015-03-04 | — | — | CN | disclosed |
| CN-102176940-B | Inhaler with indexing associated with cover movement | ASTRAZENECA AB (SE) | 2014-10-01 | — | — | CN | disclosed |
| CN-102245238-B | Breath actuated inhaler | ASTRAZENECA AB | 2014-09-10 | — | — | CN | disclosed |
| CN-103930147-A | Inhaler | ASTRAZENECA AB | 2014-07-16 | — | — | CN | disclosed |
| CN-103930146-A | Inhaler | ASTRAZENECA AB | 2014-07-16 | — | — | CN | disclosed |
| CN-103118726-A | Inhaler | ASTRAZENECA AB | 2013-05-22 | — | — | CN | disclosed |
| CN-102858640-A | Process for providing a filled canister for an inhaler | ASTRAZENECA UK LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102245239-A | Inhalation device and method of dispensing a medicament | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| CN-102245238-A | Breath actuated inhaler | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| CN-102176940-A | Inhaler with indexing associated with cover movement | ASTRAZENECA AB | 2011-09-07 | — | — | CN | disclosed |
| CN-102176939-A | Inhaler with audible indicator means | ASTRAZENECA AB | 2011-09-07 | — | — | CN | disclosed |
| CN-102131505-A | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity | ASTRAZENECA AB | 2011-07-20 | — | — | CN | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| CN-101652137-A | Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone | ASTRAZENECA AB SE | 2010-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | CHRM3 11/4885CHRM2 7/4885CHRM4 28/4885 |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | CHRM3 12/4885CHRM2 7/4885CHRM4 28/4885 |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | CHRM3 11/4885CHRM2 7/4885CHRM4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.